Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594333 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Inflammation Reduction Trial
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,786
- Enrollment target
NCT01594333 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 4,786 participants.
The verdict
NCT01594333, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,786 participants
- Enrollment target
Study Summary
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Interventions
- DRUG Placebo
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,786 participants |
| Start Date | 2013-04 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01594333
The ClinicalTrials.gov registry entry for NCT01594333 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,786 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01594333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01594333 about?
NCT01594333 is a clinical study titled "Cardiovascular Inflammation Reduction Trial". The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This tri...
What is the current status of trial NCT01594333?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,786 participants. The study started on 2013-04. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT01594333?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT01594333?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.